FDA has extended the transition period to period to August 2, 2012, with the following requirements: United States Customers currently using the STERIS System 1 (SS1) may continue to receive System 1 sterilant and other support after February 2, 2012, only if those Customers have placed orders for products to replace all remaining SS1’s in…
Eclectic Institute Dietary Supplements: Recall
<!– –> <!– Page Last Updated: 12/22/2011 –> Page Last Updated: 12/22/2011 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Liquid Acetaminophen marketed for infants: Drug Safety Communication
[Posted 12/22/2011] AUDIENCE: Pediatrics, Consumers, Pharmacy ISSUE: The FDA is informing the public that an additional concentration of liquid acetaminophen marketed for “infants†(160 mg/5 mL) is now available. This change in the concentration will affect the amount of liquid given to an infant, and should be especially noted if someone is accustomed to using…
Consumer Information on: Elecsys® Anti-HBc IgM Immunoassay and Elecsys® PreciControl Anti-HBc IgM for use on the MODULAR ANALYTICS E170 Immunoassay Analyzer
<!– –> <!– Page Last Updated: 12/21/2011 –> Page Last Updated: 12/21/2011 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
St. Jude Medical, Riata and Riata ST Silicone Endocardial Defibrillation Leads: Class 1 Recall
<!– –> <!– Page Last Updated: 12/21/2011 –> Page Last Updated: 12/21/2011 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
ShoulderFlex Massager: Warning
<!– –> <!– Page Last Updated: 12/21/2011 –> Page Last Updated: 12/21/2011 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: Safety review of a reported death after the first dose of Multiple Sclerosis drug Gilenya (fingolimod)
Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary  Safety Announcement [12-20-2011] The U.S. Food and Drug Administration (FDA) has received a report of a patient with multiple sclerosis (MS) who died within 24 hours of taking the first dose of Gilenya (fingolimod). At this time, FDA cannot conclude whether the drug resulted…
Class I Medical Device Recall: St. Jude Medical, Riata and Riata ST Silicone Endocardial Defibrillation Leads
Recall Class: Class I Date Recall Initiated: November 28, 2011 Product(s): Riata and Riata ST Silicone Endocardial Defibrillation Leads Model/catalog/lot numbers:Riata (8F) Silicone Endocardial Defibrillation LeadsModels: 1560, 1561, 1562, 1570, 1571, 1572, 1580, 1581, 1582, 1590, 1591, 1592 Riata ST (7Fr) Silicone Endocardial Defibrillation Leads Models: 7000, 7001, 7002, 7010, 7011, 7040, 7041, 7042 Distribution…
Guidance for Industry and Food and Drug Administration Staff
Document issued on: December 20, 2011 The draft of this document was issued on July 12, 2011. For questions regarding this document, contact Scott McFarland at 301-796-6217, or via email at [email protected]@fda.hhs.gov. U.S. Department of Health and Human ServicesFood and Drug AdministrationCenter for Devices and Radiological Health Preface You should submit comments and suggestions regarding…
Gilenya (fingolimod): Drug Safety Communication
<!– –> <!– Page Last Updated: 12/20/2011 –> Page Last Updated: 12/20/2011 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.